In August 2013, Compugen entered into a collaboration and license agreement with Bayer for the research, development, and commercialization of immuno-oncology therapeutics against novel targets identified by Compugen. From this collaboration, BAY 1905254, a first-in-class antibody targeting ILDR2 is expected to start human clinical trials in 2018. The companies collaborated to develop the lead antibody program targeting ILDR2, a novel B7/CD28-like immune checkpoint target, and Bayer controls all clinical development and commercialization activities worldwide.
Compugen has received $25 million in upfront and preclinical milestone payments, and is eligible to receive over $250 million in total milestone payments, as well as tiered royalties on global sales.
“At Bayer HealthCare, we are impressed with Compugen’s ability to identify novel immune checkpoints through the use of their predictive discovery infrastructure, and are pleased to collaborate with their professional scientific team on therapeutic antibody development in the field of immuno-oncology.”
Karl Ziegelbauer, Head of Global Therapeutic Research Groups at Bayer HealthCare